[Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis].
OBJECTIVE
To investigate the mechanism of tazarotene against active psoriasis vulgaris.


METHODS
A randomized, controlled trial was conducted in 43 patients with active psoriasis vulgaris, who were divided into tazarotene and control groups. Promyelocytic leukemia (PML) mRNA in active psoriatic lesions before and 14 days after tazarotene treatment was detected by in situ hybridization.


RESULTS
PML mRNA expression was detected not only in the basal layer (86.96%), but also in the suprabasal layers of the epidermis in the manner of focal expression (78.26%). After tazarotene treatment, virtually no PML mRNA expression could be detected in the psoriatic lesions (8.69% in the basal layer and 4.35% in the suprabasal layers). PML mRNA expression in the control group underwent no obvious changes during the observation.


CONCLUSIONS
Tazarotene may inhibit abnormal proliferation of keratinocytes through down-regulating PML gene expression in active psoriatic epidermis.
Wang
Qiong-yu
QY
Department of Dermatology, Second Hospital of Xi'an Jiaotong University, Xi'an 710004, China. wqy0811@163.com
Yan
Hu-ling
HL
Liu
Ping
P
Peng
Zhen-hui
ZH
Tan
Sheng-shun
SS
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D004817:Epidermis / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D017403:In Situ Hybridization; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D009687:Nuclear Proteins / Q000235:genetics*; D000071156:Promyelocytic Leukemia Protein; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics*; D012176:Retinoids
D007641:Keratolytic Agents; D009363:Neoplasm Proteins; D009539:Nicotinic Acids; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D012333:RNA, Messenger; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human; C086827:tazarotene; D012176:Retinoids